HPV and Cancer
November 12 – 13, Amsterdam, The Netherlands
Latest professional practice and future clinical management
Human papillomavirus (HPV) is purported to be the proximate cause of 10% of malignant diseases in women, and HPV-associated cancers account for 5% of the total global cancer burden. These include those of the cervix, vagina, vulva, anus, and oropharynx, and, more recently, those of the head and neck region. Although the link between HPV and cancer has been sufficiently proven, much uncertainty surrounds the effect of the new HPV vaccines on these cancers and the future clinical management of HPV-associated cancers.
This conference will provide an opportunity for regional and international leaders from the oncology community to address the growing public-health and daily practice issues associated with HPV and cancer.
Why should you attend?
This dual-stream conference will combine state-of-the-art lectures, with the opportunity for delegates to debate the critical issues with thought leaders at the highest level.
It is anticipated that participants will benefit from:
- A greater understanding of the impact of HPV and associated cancers on public health
- Enhanced knowledge and up-to-date scientific insight in HPV risk management and testing
- An update on multimodal strategies to prevent and treat HPV-associated cancers
- An opportunity to discuss perspectives and exchange ideas for the future management of HPV-associated cancers
- An insight into fundamental public health and operation strategies to bring about change
Who should attend?
The meeting will be of particular interest to:
- Physicians—infectious disease, obstetrics & gynaecology, oncology, women’s health
- Primary care teams
- Clinical researchers
- Public healthcare workers
- Allied healthcare workers
- Medical charities and patient organisations